J.Molner AS (OTSE:MOLNR) PEG Ratio: N/A (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OTSE:MOLNR J.Molner AS OTSE:MOLNR
40 GF Score
Price €18.90
GF Value €19.62
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is J.Molner AS PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, J.Molner AS's PE Ratio without NRI is 258.90. J.Molner AS's 5-Year EBITDA growth rate is 0.00%. Therefore, J.Molner AS's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for J.Molner AS's PEG Ratio or its related term are showing as below:



OTSE:MOLNR's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.74
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


J.Molner AS  (OTSE:MOLNR) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


J.Molner AS PEG Ratio Related Terms


J.Molner AS PEG Ratio Historical Data

* Premium members only.

The historical data trend for J.Molner AS's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

J.Molner AS PEG Ratio Chart

J.Molner AS Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
0.00 0.00 0.00 0.00 0.00

J.Molner AS Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
PEG Ratio Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

OTSE:MOLNR vs ZTS, UTHR, VTRS: PEG Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, J.Molner AS's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


J.Molner AS PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, J.Molner AS's PEG Ratio distribution charts can be found below:

* The bar in red indicates where J.Molner AS's PEG Ratio falls into.


OTSE:MOLNR
40GF Score
J.Molner AS OTSE:MOLNR
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

J.Molner AS PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

J.Molner AS's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=258.90410958904/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is J.Molner AS (OTSE:MOLNR) Overvalued in 2026?

Based on GuruFocus' analysis, J.Molner AS stock appears to be undervalued. The current stock price of €18.90 is trading 3.7% below its estimated GF Value™ of €19.62. GuruFocus considers J.Molner AS to be Fairly Valued.

Key valuation signals for OTSE:MOLNR:

  • PEG Ratio: N/A
  • GF Value™: €19.62 vs. price of €18.90 (3.7% below fair value)
  • GF Score™: 40/100 with 7 warning signs

No single metric tells the full story. See the OTSE:MOLNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


J.Molner AS Business Description

Address Akadeemia tee 21/5, Harju maakond, Tallinn, EST, 12618
J.Molner AS is an Estonia-based company engaged in research and development in the field of biotechnology. It is developing a portfolio of generic drug products for the United States and Canadian markets, consisting of both in-house developed medicines and acquired and in-licensed products. It operates through two complementary business units: internal generic drug development and specialized pharmaceutical services. It develops and commercializes sterile injectable, ophthalmic, and dermatology generic drugs, while also providing drug development services, analytical chemistry and stability testing. Its activities are divided into two business segments, Generic Drugs and Services, with Services generating maximum revenue. The Company generates maximum revenue from the United States.
40GF Score

Get the complete analysis for OTSE:MOLNR

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.90
Price
€19.62
GF Value